Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

5.18
-0.3250-5.90%
Volume:1.38M
Turnover:7.35M
Market Cap:762.49M
PE:-8.84
High:5.60
Open:5.55
Low:5.17
Close:5.51
52wk High:6.60
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:1.23
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:6.12
PE(LYR):-9.77

Loading ...

Aclaris CEO Neal Walker Joins Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Aclaris Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Sep 02

Aclaris Therapeutics, Inc. : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $10

THOMSON REUTERS
·
Sep 01

Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target

MT Newswires Live
·
Sep 01

Aclaris Therapeutics initiated with a Buy at Canaccord

TIPRANKS
·
Sep 01

U.S. Research Roundup-Autodesk, Hubspot, Oracle

Reuters
·
Sep 01

Piper Sandler Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)

TIPRANKS
·
Aug 31

Aclaris Therapeutics Enters Amended At-the-Market Equity Sales Agreement with Leerink, Cantor

Reuters
·
Aug 07

Aclaris Says FDA Grants Fast Track Status for Modzatinib in Moderate to Severe Lichen Planus

Reuters
·
Aug 07

Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib

Dow Jones
·
Aug 07

Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib

TIPRANKS
·
Aug 07

Aclaris Therapeutics, Inc. Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Aug 07

Aclaris Therapeutics, Inc.: Expects to Initiate a Phased Multi-Part Phase 2B Trial of Modzatinib in Lp in Q4 of 2026

THOMSON REUTERS
·
Aug 07

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (Lp)

THOMSON REUTERS
·
Aug 07

Craig-Hallum Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)

TIPRANKS
·
Aug 06

Aclaris Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Aclaris Q2 FY26 Net Loss Widens to $21.5 Million; Revenue Slips to $1.6 Million

Reuters
·
Aug 06

Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates

Reuters
·
Aug 06

Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss

MT Newswires Live
·
Aug 06

Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate

Benzinga Earnings
·
Aug 06